Neogenomics, Inc.
NEO
$7.42
$0.294.07%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 10.10% | 11.65% | 12.06% | 13.89% | 15.27% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 10.10% | 11.65% | 12.06% | 13.89% | 15.27% |
Cost of Revenue | 5.37% | 6.75% | 6.67% | 8.81% | 9.25% |
Gross Profit | 16.70% | 18.60% | 19.92% | 21.52% | 24.83% |
SG&A Expenses | 6.34% | 7.57% | 4.33% | 2.99% | 3.24% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 6.48% | 7.42% | 5.83% | 5.56% | 5.66% |
Operating Income | 17.01% | 18.56% | 26.95% | 30.70% | 31.41% |
Income Before Tax | 13.63% | 16.91% | 25.62% | 33.52% | 34.91% |
Income Tax Expenses | 84.42% | 78.65% | 80.87% | 54.90% | 52.16% |
Earnings from Continuing Operations | 7.89% | 10.51% | 19.31% | 31.50% | 32.95% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 7.89% | 10.51% | 19.31% | 31.50% | 32.95% |
EBIT | 17.01% | 18.56% | 26.95% | 30.70% | 31.41% |
EBITDA | 70.82% | 74.88% | 80.85% | 72.89% | 68.36% |
EPS Basic | 8.79% | 11.33% | 20.05% | 32.15% | 33.61% |
Normalized Basic EPS | 18.54% | 22.46% | 33.95% | 38.01% | 40.53% |
EPS Diluted | 8.70% | 11.70% | 20.31% | 32.14% | 33.84% |
Normalized Diluted EPS | 18.54% | 22.46% | 33.95% | 38.01% | 40.53% |
Average Basic Shares Outstanding | 0.96% | 0.92% | 0.92% | 0.92% | 0.97% |
Average Diluted Shares Outstanding | 0.96% | 0.92% | 0.92% | 0.92% | 0.97% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |